# US 2022/0088042 A1 · Combination therapy including sapc-dops for the treatment of pancreatic cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0088042 A1
- Document ID: US20220088042A1
- Status: Published application
- Kind: A1
- Application number: 17/327,863
- Filed: 2021-05-24
- Published: 2022-03-24
- Earliest claimed: 2016-11-21
- Assignees: Bexion Pharmaceuticals Inc.; University of Cincinnati
- Applicants: Bexion Pharmaceuticals, Inc.; University of Cincinnati
- Inventors: Xiaoyang Qi; Olugbenga Olowokure; Ray Takigiku
- Web page: https://patentgrep.com/patent/US20220088042A1

## CPC

- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/695: Silicon compounds
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61P 35/00: Antineoplastic agents
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein, according to the present invention, are methods of treating pancreatic cancer comprising administering a first pharmaceutical composition comprising Saposin C and dioleoylphosphatidylserine (SapC-DOPS) and administering a second pharmaceutical composition comprising an anti-neoplastic agent. Optionally, additional pharmaceutical compositions may be administered. Also disclosed are methods of inhibiting tumor growth. Also disclosed are kits for the treatment of pancreatic cancer comprising at least two pharmaceutical compositions, wherein a first pharmaceutical composition comprises SapC-DOPS and wherein a second pharmaceutical composition comprises a first antineoplastic agent. Also disclosed herein are combination therapeutics comprising a first pharmaceutical composition comprising SapC-DOPS and at least a second pharmaceutical composition comprising an antineoplastic agent, wherein the first and second pharmaceutical compositions are formulated separately to be used in the form of a kit where they are present together.

## Claims

### Claim 1

A method of treating pancreatic cancer comprising administering a first pharmaceutical composition comprising Saposin C and dioleoylphosphatidylserine (SapC-DOPS) and administering a second pharmaceutical composition comprising an antineoplastic agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the SapC-DOPS is present in nanovesicles.

### Claim 3 (depends on 1)

The method of claim 1, wherein the antineoplastic agent comprises gemcitabine, nab-paclitaxel, Folfirinox, or a combination thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the first pharmaceutical composition is administered contemporaneously or sequentially with the second pharmaceutical composition.

### Claim 5 (depends on 1)

The method of claim 1, wherein the administering of the first pharmaceutical composition comprises an intravenous route.

### Claim 6 (depends on 1)

The method of claim 1, wherein the administering of the second pharmaceutical composition comprises an intravenous route.

### Claim 7 (depends on 1)

The method of claim 1, wherein the administering of the second pharmaceutical composition results in increased external neoplastic cell membrane surface levels of phosphatidylserine (PS).

### Claim 8 (depends on 1)

The method of claim 1, further comprising a third pharmaceutical composition.

### Claim 9 (depends on 8)

The method of claim 8, wherein the first pharmaceutical composition comprises SapC-DOPS at a dose of 2.4 mg/kg and the administering of the first pharmaceutical composition occurs at least once per week, the second pharmaceutical composition comprises gemcitabine at a dose of 1000 mg/m2, and the third composition comprises nab-paclitaxel at a dose of 100 mg/m2.

### Claim 10 (depends on 9)

The method of claim 9, wherein the administering of the first pharmaceutical composition occurs at least three times per week, the administering of the second pharmaceutical composition occurs one time per week, or combinations thereof.

### Claim 11

A method of inhibiting tumor growth comprising administering a first pharmaceutical composition comprising SapC-DOPS and administering a second pharmaceutical composition comprising an antineoplastic agent.

### Claim 12 (depends on 11)

The method of claim 11, wherein the second pharmaceutical composition comprises gemcitabine, nab-paclitaxel, Folfirinox, or a combination thereof.

### Claim 13 (depends on 11)

The method of claim 11, wherein the first pharmaceutical composition is administered contemporaneously or sequentially with the second pharmaceutical composition.

### Claim 14 (depends on 11)

The method of claim 11, further comprising a third pharmaceutical composition.

### Claim 15 (depends on 14)

The method of claim 14, wherein first pharmaceutical composition comprises SapC-DOPS at a dose of 2.4 mg/kg and the administering of the first pharmaceutical composition occurs at least once per week, the second pharmaceutical composition comprises gemcitabine at a dose of 1000 mg/m2, and the third composition comprises nab-paclitaxel at a dose of 100 mg/m2.

### Claim 16 (depends on 15)

The method of claim 15, wherein the administering of the first pharmaceutical composition occurs at least three times per week.

### Claim 17

A kit for the treatment of pancreatic cancer comprising at least two pharmaceutical compositions, wherein a first pharmaceutical composition comprises SapC-DOPS and wherein a second pharmaceutical composition comprises a first antineoplastic agent.

### Claim 18 (depends on 17)

The kit of claim 17, wherein the kit further comprises instructions for administering the first and the second pharmaceutical compositions.

### Claim 19 (depends on 17)

The kit of claim 17, wherein the second pharmaceutical composition comprises gemcitabine.

### Claim 20 (depends on 17)

The kit of claim 17, further comprising a third pharmaceutical composition comprising a second antineoplastic agent, the kit further comprising instructions for administering the third pharmaceutical composition.

### Claim 21 (depends on 20)

The kit of claim 20, wherein the third pharmaceutical composition comprises nab-paclitaxel.

### Claim 22 (depends on 20)

The kit of claim 20, wherein first pharmaceutical composition comprises SapC-DOPS at a dose of 2.4 mg/kg and the instructions instruct administering the first pharmaceutical composition at least once per week, the second pharmaceutical composition comprises gemcitabine at a dose of 1000 mg/m2, and the third composition comprises nab-paclitaxel at a dose of 100 mg/m2.

### Claim 23 (depends on 22)

The method of claim 22, wherein the instructions instruct administering the first pharmaceutical composition at least three times per week.

### Claim 24 (depends on 17)

The kit of claim 17, wherein the second pharmaceutical composition comprises Folfirinox.

### Claim 25 (depends on 24)

The kit of claim 24, wherein the instructions instruct administering Folfirinox intravenously as an infusion.

### Claim 26

A combination therapeutic comprising a first pharmaceutical composition comprising SapC-DOPS and a second pharmaceutical composition comprising at least one antineoplastic agent, wherein the first and the second pharmaceutical compositions are formulated separately to be used in the form of a kit where they are present together.

### Claim 27 (depends on 26)

The combination therapeutic of claim 26, further comprising a third pharmaceutical composition comprising a second antineoplastic agent formulated separately to be used in the kit.
